BioCentury
ARTICLE | Clinical News

MORAb-004: Phase I data

May 30, 2011 7:00 AM UTC

An ongoing, dose-escalation, open-label, U.S. Phase I trial in 23 patients with refractory solid tumors showed that IV MORAb-004 produced 3 minor responses, plus 5 cases of durable stable disease for ...